Belimumab: In systemic lupus erythematosus

Drugs

Volumn 71, Issue 18, 2011, Pages 2435-2444

  Burness, Celeste B ^a   McCormack, Paul L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Belimumab; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; B CELL ACTIVATING FACTOR; BELIMUMAB; CD20 ANTIBODY; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN G1 ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RECOMBINANT ANTIBODY;

B LYMPHOCYTE; BRONCHITIS; CANADA; CELL DIFFERENTIATION; CELL SURVIVAL; DEPRESSION; DIARRHEA; DISEASE ACTIVITY; DOSE RESPONSE; DRUG FATALITY; EUROPEAN UNION; FATAL FAMILIAL INSOMNIA; FEVER; HUMAN; IC 50; LIMB PAIN; MIGRAINE; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES;

EID: 82955169564     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11208440-000000000-00000     Document Type: Review

References (24)

1. Crispin JC, Liossis S-NC, Kis-Toth K, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010; 16 (2): 47-57
2. Lupus Foundation of America. What is lupus [online]. Available from URL: http://www.lupus.org/webmodules/webarticlesnet/templates/new-learnunderstanding. aspx? articleid=2232&zoneid=523 [Accessed 2011 Nov 11]
3. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum 2008 Jan; 58 (1): 15-25
4. The American College of Rheumatology. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum 1999 Sep; 42 (9): 1785-96
5. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009 May; 119 (5): 1066-73
6. Mitka M. Treatment for lupus, first in 50 years, offers modest benefits, hope to patients. JAMA 2011 May 4; 305 (17): 1754-5
7. Human Genome Sciences. Benlysta (belimumab): US prescribing information [online]. Available from URL: http://www.hgsi.com/images/Benlysta/pdf/benlysta pi.pdf [Accessed 2011 Nov 11]
8. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003 Nov; 48 (11): 3253-65 (Pubitemid 37409340)
9. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009 Sep 15; 61 (9): 1168-78
10. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011 Feb 26; 377 (9767): 721-31
11. Furie R, Petri M, Zamani O, et al. A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits BLyS, in patients with systemic lupus erythematosus. Arthritis Rheum. In press
12. Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008 Sep; 10 (5): R109
13. Jacobi AM, Huang W, Wang T, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebocontrolled, dose-ranging study. Arthritis Rheum 2010 Jan; 62 (1): 201-10
14. Stohl W, Hiepe F, Thomas M, et al. Belimumab, a BLySspecific inhibitor, significantly reduced autoantibodies, normalized low complement, and reduced selected B-cell populations in patients with seropositive systemic lupus erythematosus (SLE): the phase 3 BLISS studies [abstract no. 1146]. 74th Annual Scientific Meeting of the American College of Rheumatology and the 45th AnnualMeeting of the Association of Rheumatology and Health Professionals; 2010 Nov 6-11; Atlanta (GA)
15. European Medicines Agency. Benlysta (belimumab): summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR---Product-Information/human/002015/WC 500110150.pdf [Accessed 2011 Nov 11]
16. Human Genome Sciences. Arthritis Advisory Committee Meeting briefing document for the 16 November 2010 meeting [online]. Available from URL: http://www.fda. gov/downloads/AdvisoryCommittees/CommitteesMeeting Materials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM 233581.pdf [Accessed 2011 Nov 11]
17. Food and Drug Administration (FDA). Briefing document for the Arthritis Advisory Committee meeting: November 16, 2010 [online]. Available from URL: http://www.fda. gov/downloads/advisorycommittees/committeesmeeting materials/drugs/arthritisdrugsadvisorycommittee/ucm233579. pdf [Accessed 2011 Nov 11]
18. Furie RA, Petri MA, Wallace DJ, et al. Novel evidencebased systemic lupus erythematosus responder index. Arthritis Rheum 2009 Sep 15; 61 (9): 1143-51
19. Cervera R, Furie R, Levy R, et al. Relationship of belimumab treatment response with corticosteroid use and severe flares in patients with SLE: Bliss-52 and Bliss-76 [abstract no. THU0430]. 12th Annual Congress of the European League Against Rheumatism; 2011 May 25-28; London
20. Wallace DJ, Navarra S, Gallacher A, et al. Safety profile of belimumab, a BLyS-specific inhibitor, in patients with active systemic lupus erythematosus (SLE): pooled data from phase 2 and 3 studies [abstract no. 1172]. 74th Annual Scientific Meeting of the American College of Rheumatology and the 45th Annual Meeting of the Association of Rheumatology and Health Professionals; 2010 Nov 6-11; Atlanta (GA)
21. Merrill JT, Furie RA, Wallace DJ, et al. Sustained disease improvement and safety profile over the 1500 patient-year experience (6 years) with belimumab in patients with systemic lupus erythematosus [abstract no. 584]. 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology Health Professionals; 2011 Nov 4-9; Chicago (IL)
22. Health Canada. Notice of decision for Benlysta [online]. Available from URL: http://www.hc-sc.gc.ca/dhp-mps/alt-formats/pdf/prodpharma/sbd-smd/phase1- decision/drugmed/nd ad 2011-benlysta 137699-eng.pdf [Accessed 2011 Nov 11]
23. Human Genome Sciences. A continuation trial for subjects with lupus who completed protocolHGS1006-C1056 in the United States [ClinicalTrials.gov identifier NCT00724867]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00724867
24. Human Genome Sciences. A continuation trial for subjects with lupus that completed protocol HGS1006-C1056 or HGS1006-C1057 [ClinicalTrials.gov identifier NCT00712933]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00712933 [Accessed 2011 Nov 11]